Fig. 3: H3-nanovax encapsulating IAV proteins induces payload targeted systemic and lung-local IAV-specific antibody responses. | npj Vaccines

Fig. 3: H3-nanovax encapsulating IAV proteins induces payload targeted systemic and lung-local IAV-specific antibody responses.

From: Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection

Fig. 3

C57BL/6 mice were vaccinated with H3-nanovax encapsulating CpG + either HA/NP (Pink), NA/NP (Blue), NA/M1 (Purple), or left unvaccinated (naïve). At 45 days post-vaccination, serum and BAL were collected and serum and BAL IgG (a, b, d, e) and BAL IgA (c, f) specific for NP (A/Hong Kong/1/68, H3N2) and M1 (A/Aichi/2/68, H3N2) were quantified via ELISA. As a measure of anti-HA specific antibody against IAV A/Hong Kong/1/68 (H3N2), HAI titers in the serum and BAL were quantified (g, h). Shown is the 1:40 titer (dotted line) that is thought to be the threshold for a protective titer. LOD (dotted line) = Limit of Detection. Anti-NA antibody in serum and BAL (i, j) were quantified via fluorescence-based NAI. LOD (dotted line) = Limit of Detection; Error bars, mean ± s.e.m. Data representative of two independent experiments with n = 4 mice/group. a–j HA/NP vs. naïve: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; NA/NP vs. naïve: #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001; NA/M1 vs. naive: †P < 0.05, ††P < 0.01, †††P < 0.001, ††††P < 0.0001; HA/NP vs. NA/M1: @P < 0.05, @@P < 0.01, @@@P < 0.001, @@@@P < 0.0001, NA/NP vs. NA/M1: ǂP < 0.05, ǂǂP < 0.01, ǂǂǂP < 0.001, ǂǂǂǂP < 0.0001, (Two-way ANOVA with Tukey’s multiple comparison test). (g, h) ****P < 0.0001 (One-way ANOVA with Tukey’s multiple comparisons test).

Back to article page